At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Aug 4, 2026 at 16:30 ET
Chemours Q2 2026 Adjusted EPS of $0.42 matched consensus, but revenue of $1.591B missed the $1.66B estimate by ~4%. Adjusted EBITDA declined 5% YoY to $247M, and Q3 EBITDA guidance of $175-205M signals a sequential drop. Full-year guidance was maintained, but the weak Q3 outlook and revenue miss temper any positive read-through from in-line earnings.
- Adjusted EPS $0.42 exactly in line with consensus estimate of $0.42
- Revenue $1.591B missed consensus of $1.66B by ~4% ($69M shortfall)
- Q3 2026 Adjusted EBITDA guidance $175-205M, well below Q2 2026 actual of $247M
- Full-year 2026 EBITDA guidance maintained at $775-825M, implying modest H2 recovery
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access